US Biotechnology: CYTK & IONS – Quick Take on ESC Late-Breaker Update

Research evidence excerpt

US Biotechnology: CYTK & IONS – Quick Take on ESC Late-Breaker Update

Flash |

07 Jul 2026 10:29:54 ET │ 10 pages

US Biotechnology

CYTK & IONS – Quick Take on ESC Late-Breaker Update

CITI'S TAKE

With the ESC late-breaker lineup announced this morning, we wanted to

offer some incremental thoughts on CYTK and IONS, both with pivotal

programs prominently positioned at the medical congress. Although

there's little detail beyond the title info, for CYTK, we incrementally Eric Joseph, PhDAC

encouraged by ACACIA-HCM results being featured across two late- +1-212-816-8697

breaking sessions (details below) that together we suspect will relate eric.joseph@citi.com

heart remodeling to symptom improvement, and solidify Myqorzo’s

regulatory and commercial outlook in non-obstructive HCM. For IONS, the

Hot Line presentation slot for CARDIO-TTRansform does have us

pleasantly surprised. That said, we'd resist over-inferring beyond the

narrowed timeframe to a potential topline readout (alongside Astra’s 2Q

results feels increasingly likely; AZN covered by Graham Parry) to the

strength of trial results (our published views and investor feedback into

CARDIO-TTRansform here and here).

CYTK will present additional data from the ACACIA-HCM study since topline

across two late-breaking sessions and further MAPLE-HCM data.

1. ACACIA-HCM: Aficamten for Symptomatic Nonobstructive Hypertrophic

Cardiomyopathy on Aug. 28, 11:45am CEST (session link)

2. Effect of Aficamten on Cardiac Structure and Function in Patients with

Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - Results from

the ACACIA-HCM Trial on Aug. 29, 4:15pm CEST (session link)

3. Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic

Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM on Aug.